Literature DB >> 12970421

Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors.

Saw See Hong1, Nagy A Habib, Laure Franqueville, Steen Jensen, Pierre A Boulanger.   

Abstract

Sera from 17 patients with primary and secondary liver tumors who had been administered oncolytic adenovirus (Ad) mutant Addl1520 were analyzed for anti-Ad neutralization titers and antibodies to the Ad major capsid proteins hexon, penton base (Pb), and fiber. The antibodies recognized mainly conformational epitopes in hexon and both linear and conformational epitopes in Pb and fiber. Pb-specific antibodies were isolated from serum samples that had been obtained prior to and during the course of the treatment of four of these patients. We found that the Pb antibodies had a significant contribution toward anti-Ad neutralization, and this mainly occurred at the step of virus internalization. The Pb antigenic epitopes were determined by phage biopanning and were mapped to 10 discrete regions, which made up three major immunodominant domains within residues 51 to 120, 193 to 230, and 311 to 408, respectively. One of these domains (residues 311 to 408) overlapped the highly conserved, integrin-binding RGD (Arg-Gly-Asp) motif. The contribution of antibodies directed to RGD and other epitopes in Ad neutralization activity was determined indirectly by using a phage-mediated depletion assay. Our results suggested that circulating RGD antibodies were not prevalent and were poorly neutralizing and that other peptide motifs within residues 51 to 60, 216 to 226, and 311 to 408 in Pb sequence represented major target sites for neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970421      PMCID: PMC228409          DOI: 10.1128/jvi.77.19.10366-10375.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Rapid assessment of adenovirus serum neutralizing antibody titer based on quantitative, morphometric evaluation of capsid binding and intracellular trafficking: population analysis of adenovirus capsid association with cells is predictive of adenovirus infectivity.

Authors:  T Vincent; B G Harvey; S M Hogan; C J Bailey; R G Crystal; P L Leopold
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients.

Authors:  Y Stallwood; K D Fisher; P H Gallimore; V Mautner
Journal:  Gene Ther       Date:  2000-04       Impact factor: 5.250

3.  Mapping of linear epitopes on fibre knob of human adenovirus serotype 5.

Authors:  H Liebermann; K Lotz; R Mentel; U Bauer; W Seidel
Journal:  Virus Res       Date:  2001-03       Impact factor: 3.303

4.  Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon.

Authors:  J J Rux; R M Burnett
Journal:  Mol Ther       Date:  2000-01       Impact factor: 11.454

5.  A triple beta-spiral in the adenovirus fibre shaft reveals a new structural motif for a fibrous protein.

Authors:  M J van Raaij; A Mitraki; G Lavigne; S Cusack
Journal:  Nature       Date:  1999-10-28       Impact factor: 49.962

6.  Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity.

Authors:  H Gahéry-Ségard; F Farace; D Godfrin; J Gaston; R Lengagne; T Tursz; P Boulanger; J G Guillet
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

7.  The first step of adenovirus type 2 disassembly occurs at the cell surface, independently of endocytosis and escape to the cytosol.

Authors:  M Y Nakano; K Boucke; M Suomalainen; R P Stidwill; U F Greber
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

8.  Immunoreactive domains and integrin-binding motifs in adenovirus penton base capsomer.

Authors:  S S Hong; M Bardy; M Monteil; B Gay; C Denesvre; J Tournier; G Martin; M Eloit; P Boulanger
Journal:  Viral Immunol       Date:  2000       Impact factor: 2.257

9.  Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy.

Authors:  Y Chen; D C Yu; D Charlton; D R Henderson
Journal:  Hum Gene Ther       Date:  2000-07-20       Impact factor: 5.695

10.  E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors.

Authors:  N A Habib; C E Sarraf; R R Mitry; R Havlík; J Nicholls; M Kelly; C C Vernon; D Gueret-Wardle; R El-Masry; H Salama; R Ahmed; N Michail; E Edward; S L Jensen
Journal:  Hum Gene Ther       Date:  2001-02-10       Impact factor: 5.695

View more
  29 in total

1.  Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions.

Authors:  Ritu R Bradley; Lori F Maxfield; Diana M Lynch; Mark J Iampietro; Erica N Borducchi; Dan H Barouch
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection.

Authors:  Ritu R Bradley; Diana M Lynch; Mark J Iampietro; Erica N Borducchi; Dan H Barouch
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

3.  Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity.

Authors:  Anja Krause; Ju H Joh; Neil R Hackett; Peter W Roelvink; Joseph T Bruder; Thomas J Wickham; Imre Kovesdi; Ronald G Crystal; Stefan Worgall
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  Phylogenetic analysis and structural predictions of human adenovirus penton proteins as a basis for tissue-specific adenovirus vector design.

Authors:  Ijad Madisch; Soeren Hofmayer; Christian Moritz; Alexander Grintzalis; Jens Hainmueller; Patricia Pring-Akerblom; Albert Heim
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

Review 5.  Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach.

Authors:  Qiana L Matthews
Journal:  Mol Pharm       Date:  2010-12-01       Impact factor: 4.939

6.  Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization.

Authors:  Cheng Cheng; Jason G D Gall; Martha Nason; C Richter King; Richard A Koup; Mario Roederer; M Juliana McElrath; Cecilia A Morgan; Gavin Churchyard; Lindsey R Baden; Ann C Duerr; Michael C Keefer; Barney S Graham; Gary J Nabel
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

7.  Directed evolution of mutator adenoviruses resistant to antibody neutralization.

Authors:  Nicolle D Myers; Ksenia V Skorohodova; Anshu P Gounder; Jason G Smith
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

8.  Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.

Authors:  Issa Nébié; Nick J Edwards; Alfred B Tiono; Katie J Ewer; Guillaume S Sanou; Issiaka Soulama; Souleymane Sanon; Amidou Diarra; Jean Baptiste Yaro; David Kangoye; Egeruan B Imoukhuede; Adrian V S Hill; Sodiomon B Sirima
Journal:  Clin Vaccine Immunol       Date:  2014-04-16

9.  Detection of antibodies against adenovirus protein IX, fiber, and hexon in human sera by immunoblot assay.

Authors:  Ulrike Bauer; Gisela Flunker; Kornelia Bruss; Knut Kallwellis; Herbert Liebermann; Tanja Luettich; Manfred Motz; Werner Seidel
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

10.  Fiber mediated receptor masking in non-infected bystander cells restricts adenovirus cell killing effect but promotes adenovirus host co-existence.

Authors:  Johan Rebetz; Manli Na; Changqing Su; Bo Holmqvist; Anna Edqvist; Cecilia Nyberg; Bengt Widegren; Leif G Salford; Hans Olov Sjögren; Niklas Arnberg; Qijun Qian; Xiaolong Fan
Journal:  PLoS One       Date:  2009-12-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.